Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial-Reference-Cited by-同舟云学术

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Published:2021-03 Issue:3 Volume:99 Page:750-762
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Kraus Bettina J.,Weir Matthew R.,Bakris George L.,Mattheus Michaela,Cherney David Z.I.,Sattar Naveed,Heerspink Hiddo J.L.,Ritter Ivana,von Eynatten Maximilian,Zinman Bernard,Inzucchi Silvio E.,Wanner Christoph,Koitka-Weber Audrey

Publisher

Elsevier BV

Subject

Nephrology

Reference59 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

5. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial;Mosenzon;Lancet Diabetes Endocrinol,2019

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?;Heart Failure Clinics;2024-10

2. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions;American Journal of Physiology-Cell Physiology;2024-09-01

3. SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health;Kidney Medicine;2024-08

4. Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung;Aktuelle Kardiologie;2024-07-31

5. Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip;Clinical and Experimental Nephrology;2024-07-06